Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VBAMDex chemotherapy in advanced multiple myeloma.

D Peest1, H J Schmoll, I Schedel

  • 1Abt. Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Germany.

European Journal of Haematology
|March 1, 1988
PubMed
Summary

This phase II study shows a five-drug regimen (vincristine, BCNU, adriamycin, melphalan, dexamethasone) achieved significant remissions in advanced multiple myeloma patients, including those resistant to prior chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Therapy of multiple myeloma. What is confirmed?].

Der Internist·2013
Same author

Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation.

Vox sanguinis·2013
Same author

[Therapy of multiple myeloma: indications and options].

Der Internist·2007
Same author

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.

Bone marrow transplantation·2003
Same author

[Multilocular Castleman's Disease of the mixed type. An rare differential diagnosis in lymphadenopathy with weakness, weight loss and night-sweats].

Deutsche medizinische Wochenschrift (1946)·2001
Same author

Tumor necrosis factor, interleukin-6,and epinephrine are associated with hypermetabolism in AIDS patients with acute opportunistic infections.

Annals of nutrition & metabolism·2000

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Advanced multiple myeloma presents treatment challenges.
  • Effective regimens for both treatment-naive and relapsed patients are needed.

Purpose of the Study:

  • To evaluate a five-drug regimen for advanced multiple myeloma.
  • To assess efficacy and toxicity in patients with and without prior chemotherapy.

Main Methods:

  • Phase II study involving 28 advanced multiple myeloma patients.
  • Treatment regimen: vincristine, BCNU, adriamycin, melphalan, and dexamethasone.
  • Patients categorized into treatment-naive and previously treated groups.

Main Results:

  • High remission rates observed in both groups (11/13 treatment-naive, 13/15 previously treated).

Related Experiment Videos

  • Significant tumor cell mass reduction (>75%) achieved in a majority of patients.
  • No tumor progression noted; median follow-up of 12.75 months with 4 relapses.
  • Bone marrow toxicity observed in 14 patients.

    • Conclusions:

    • The five-drug regimen shows promise for advanced multiple myeloma treatment.
    • Efficacy demonstrated in both treatment-naive and chemotherapy-resistant populations.
    • Further validation in prospective randomized trials is warranted.